Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy

International Journal of Infectious Diseases

Volumn 28, Issue , 2014, Pages e3-e7

  Yang, Chih Chao ^a   Wu, Chien Hsing ^a   Lee, Chien Te ^a   Liu, Han Tsung ^a   Chen, Jin Bor ^a   Chiu, Chien Hua ^a   Chen, Chih Hung ^a   Chuang, Feng Rong ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bacteremia; Ertapenem; Extended spectrum beta lactamase; Flomoxef; Hemodialysis access; Klebsiella pneumoniae

Indexed keywords

ERTAPENEM; FLOMOXEF; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIALYSIS CATHETER; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; HEMODIALYSIS PATIENT; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; SEPTICEMIA; TREATMENT INDICATION; TREATMENT OUTCOME; AGED; CROSS INFECTION; ENZYMOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; BETA-LACTAMS; CEPHALOSPORINS; CROSS INFECTION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84949117741     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.07.012     Document Type: Article

References (23)

1. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004, 44:779-791.
2. Nassar G.M., Ayus J.C. Infectious complications of the hemodialysis access. Kidney Int 2001, 60:1-13.
3. Yang C.C., Li S.H., Chuang F.R., Lee C.H., Chen J.B., Lee C.T., et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis. BMC Infect Dis 2012, 12:206.
4. Rupp M.E., Fey P.D. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63:353-365.
5. Paterson D.L., Mulazimoglu L., Casellas J.M., Ko W.C., Goossens H., Von Gottberg A., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-478.
6. Fong J.J., Rose L., Radigan E.A. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum beta-lactamase producing Gram-negative bacteria. Ann Pharmacother 2012, 46:347-352.
7. Collins V.L., Marchaim D., Pogue J.M., Moshos J., Bheemreddy S., Sunkara B., et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012, 56:2173-2177.
8. Jacoby G.A., Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990, 34:858-862.
9. Lee C.H., Su L.H., Tang Y.F., Liu J.W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006, 58:1074-1077.
10. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
11. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 18th Informational supplement. CLSI/NCCLS M100-S18. Wayne, PA: CLSI; 2008.
13. Grimm H. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef. Infection 1991, 19(Suppl 5):S258-S263.
14. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212.
15. Kim B.N., Woo J.H., Kim M.N., Ryu J., Kim Y.S. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002, 52:99-106.
16. Go E.S., Urban C., Burns J., Kreiswirth B., Eisner W., Mariano N., et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994, 344:1329-1332.
17. Rahal J.J., Urban C., Horn D., Freeman K., Segal-Maurer S., Maurer J., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280:1233-1237.
18. Sanyal S.C., Mokaddas E.M. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999, 11:28-33.
19. Bauernfeind A., Schweighart S., Eberlein E., Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection 1991, 19(Suppl 5):S264-S275.
20. Curran M., Simpson D., Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs 2003, 63:1855-1878.
21. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14:933-951. table of contents.
22. Lok C.E., Mokrzycki M.H. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int 2011, 79:587-598.
23. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.